Literature DB >> 11252300

Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.

D E Shan1, S J Lee, L Y Chao, S I Yeh.   

Abstract

OBJECTIVE: To determine the therapeutic effect of levodopa/benserazide and tolcapone on gait in patients with advanced Parkinson's disease.
METHODS: Instrumental gait analysis was performed in 38 out of 40 patients with wearing-off phenomenon during a randomized, double-blind, placebo-controlled trial of tolcapone.
RESULTS: Gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints. At the end of the study, both the UPDRS motor scores during off-period and the percentage of off time improved significantly using tolcapone. However, gait analysis could not confirm this improvement. With respect to levodopa/benserazide effect, the reduction in rigidity correlated with improved angular excursion of the ankle, whereas the decreased bradykinesia correlated with improved stride length and angular excursion of the hip and knee joints.
CONCLUSION: The results of our gait analysis confirmed that in parkinsonian patients with fluctuating motor symptoms levodopa/benserazide, but not tolcapone, produced a substantial improvement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252300     DOI: 10.1017/s0317167100052598

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  6 in total

Review 1.  Tolcapone: a review of its use in the management of Parkinson's disease.

Authors:  Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Striatal dopaminergic denervation and gait in healthy adults.

Authors:  R Cham; S A Studenski; S Perera; N I Bohnen
Journal:  Exp Brain Res       Date:  2007-11-01       Impact factor: 1.972

3.  Advances in Therapeutic Options for Gait and Balance in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Roger L Albin; Martijn L T M Müller; Kelvin Chou
Journal:  US Neurol       Date:  2011-11-01

4.  Safety and efficacy of tolcapone in Parkinson's disease: systematic review.

Authors:  Carlo Alberto Artusi; Lidia Sarro; Gabriele Imbalzano; Margherita Fabbri; Leonardo Lopiano
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

Review 5.  Utility of tolcapone in fluctuating Parkinson's disease.

Authors:  Fabrizio Stocchi; Maria Francesca De Pandis
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

6.  COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.

Authors:  Angelo Antonini; Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Marco Onofrj; Mario Zappia; Aldo Quattrone
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.